Lung disease drug tested in rare muscle condition – trial cut short
NCT ID NCT05335278
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested the drug nintedanib (Ofev) in 11 people with myositis-related interstitial lung disease, a condition where lung scarring occurs alongside muscle inflammation. The goal was to see if the drug is safe and tolerable when added to standard immune-suppressing treatments. The trial was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nintedanib (Ofev)
What this could lead to
If successful, this could show that adding nintedanib to standard care is safe and tolerable for people with myositis-related lung disease, potentially slowing disease progression.
What could go wrong
The trial was terminated early with only 11 participants, so results are very limited. It was a small, early-stage safety study, not designed to prove effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Institute McGill University Health Center
Montreal, Quebec, H4A3J1, Canada